Kiora Pharmaceuticals (KPRX) Consolidated Net Income (2016 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Consolidated Net Income came in at -$2.4 million in Q1 2026, down 10.26% YoY from -$2.7 million in Q1 2025, and up 62.79% on a QoQ basis from -$6.5 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Consolidated Net Income (2016 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 11 years of Consolidated Net Income data on file, last reported at -$2.4 million in Q1 2026.
- Quarterly Consolidated Net Income fell 10.26% year-over-year to -$2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.0 million (up 8.37% YoY) and the FY2025 annual result came in at -$10.8 million, down 400.92% from the prior year.
- Consolidated Net Income grew to -$2.4 million in Q1 2026, from -$6.5 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $13.5 million in Q1 2024 to a low of -$6.5 million in Q4 2025.
- A 5-year average of -$2.2 million and a median of -$2.5 million in 2022 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income sank 7427.78% — and 2024, when it jumped 801.62%.
- Tracing KPRX's Consolidated Net Income over 5 years: stood at -$2.5 million in 2022, then increased by 9.2% to -$2.3 million in 2023, then sank by 86.17% to -$4.2 million in 2024, then sank by 53.87% to -$6.5 million in 2025, then soared by 62.79% to -$2.4 million in 2026.
- The last three Consolidated Net Income figures came in at -$2.4 million (Q1 2026), -$6.5 million (Q4 2025), and $26806.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - | -2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.08 Mn |
| Mar 31, 2026 | -2.42 Mn |
| Dec 31, 2025 | -6.50 Mn |
| Sep 30, 2025 | 26,806.00 |
| Jun 30, 2025 | -2.15 Mn |
| Mar 31, 2025 | -2.19 Mn |
| Dec 31, 2024 | -4.22 Mn |
| Sep 30, 2024 | -3.41 Mn |
| Jun 30, 2024 | -2.22 Mn |
| Mar 31, 2024 | 13.45 Mn |
| Dec 31, 2023 | -2.27 Mn |
| Sep 30, 2023 | -6.29 Mn |
| Jun 30, 2023 | -2.67 Mn |
| Mar 31, 2023 | -1.92 Mn |
| Dec 31, 2022 | -2.50 Mn |
| Sep 30, 2022 | -5.12 Mn |
| Jun 30, 2022 | -2.58 Mn |
| Mar 31, 2022 | -3.63 Mn |
| Dec 31, 2021 | -14.39 Mn |
| Sep 30, 2021 | -68,006.00 |